Glycochenodeoxycholate and glycodeoxycholate 3‐O‐glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC‐0810 in humans
Kenta J. Yoshida, Allan Jaochico, Jialin Mao et al. · British Journal of Clinical Pharmacology · 2023
Endogenous biomarkers of drug transporters are promising tools to evaluate in vivo transporter function and potential alterations in the pharmacokinetics of their substrates. We have previously reported that coproporphyrin I/III captured the weak inhibition of OATP1B transporters by GDC‐0810. In this study, we measured plasma concentrations of additional biomarkers, namely fatty acids, bile acids and their sulphate or glucuronide conjugates in the presence and absence of GDC‐0810. Concentrations of hexadecanedioate and tetradecanedioate did not increase in the presence of GDC‐0810. Among bile acids and their conjugates, glycochenodeoxycholate and glycodeoxycholate 3‐O‐glucuronides (GCDCA‐3G and GDCA‐3G) showed Cmax increases with geometric mean ratio (95% confidence interval) of 1.58 (1.13‐2.22) and 1.49 (1.21‐1.83), consistent with previous reports from low‐dose rifampin co‐administration and pharmacogenetic studies. These results suggest that GCDCA‐3G and GDCA‐3G are two more promising biomarkers that may capture weak OATP1B inhibition in addition to coproporphyrin I/III.
Cited by 6 works. doi:10.1111/bcp.15679
Authors
References
- R: A Language and Environment for Statistical Computing
- Membrane transporters in drug development
- Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption
- Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition
- Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
- Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions
- Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects
- Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
- Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions
- Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers